Conveners
Radioisotope beams in hadron therapy
- Claus Schmitzer (MedAustron)
Radioisotope beams in hadron therapy
- Marco Giuseppe Pullia (Fondazione CNAO (IT))
- Philippe Lambin (Maastricht University)
Radiotherapy using accelerated heavy ions has the potential to overhaul cancer treatment and replace invasive techniques (surgery, catheter ablation) for selected noncancer diseases. However, particle therapy is hampered by the range uncertainty and requires more precision to fully leverage its physical advantages and expand the applications to noncancer diseases such as heart arrhythmia. The...
The relativistic high-energy heavy-ion beam gives the good localized dose distribution and the large relative biological effectiveness, thus twelve heavy-ion radiotherapy (HIRT) facilities are under operation and six are under commissioning or construction worldwide. HIRT awakens worldwide interest. It is expected that clinical results will be improved through the more concentrated dose...
Formally the neutron is the lightest radionuclide on the bottom left corner of the chart of nuclides. However, in the present context their radioactive decay is not of concern but their interaction with biological tissue. In contrast to the charged particle beams used for hadron therapy, neutrons as neutral particles are not directly ionizing. However, neutron beams can be used for boron...
The particle therapy is a major contributor to the medical application of accelerator technology and may yet be improved by the use of radioisotopes as beam species, which would allow a better traceability of the applied dose.
The Medicis-Promed network leads an initiative to study the possible technical solutions for the implementation of Carbon-11 radioisotopes in an accelerator-based...
The benefit of hadrontherapy compared to conventional radiation therapy is the higher ratio between dose to tumor and dose to normal tissue. However, regarding depth dose distribution between charged particles and photons, effect of range uncertainty is more significant with charged particles. Thus, importance of understanding range uncertainty arises. There are many sources of uncertainty,...
Within the Marie Skłodowska-Curie innovative training network MEDICIS-Promed, a $^{11}$C based carbon therapy protocol is being developed. Replacing the stable $^{12}$C beam with its radioactive isotope $^{11}$C, therapy can be combined with on-line PET-imaging. The PET-images that are recorded simultaneous with the treatment, represent a 3D dose distribution map of the irradiation field, and...
In this contribution, the possibilities of using a charge breeding scheme based on an Electron Beam Ion Source for beam preparation of a radioactive 11C beam for hadron therapy are discussed. Test measurements under extreme operating conditions were conducted at the REX-ISOLDE facility to explore the limitations of the charge breeder for high-intensity, low-repetition-rate, molecular CO+...
